SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001140361-22-024797
Filing Date
2022-07-01
Accepted
2022-07-01 16:30:48
Documents
12
Period of Report
2022-06-27
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K brhc10039316_8k.htm   iXBRL 8-K 26065
  Complete submission text file 0001140361-22-024797.txt   160938

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA btx-20220627.xsd EX-101.SCH 3929
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE btx-20220627_lab.xml EX-101.LAB 22544
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btx-20220627_pre.xml EX-101.PRE 16047
6 EXTRACTED XBRL INSTANCE DOCUMENT brhc10039316_8k_htm.xml XML 4091
Mailing Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220
Business Address 140 58TH STREET, BUILDING A SUITE 2100 BROOKLYN NY 11220 (212) 582-1199
Brooklyn ImmunoTherapeutics, Inc. (Filer) CIK: 0000748592 (see all company filings)

IRS No.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 221061863
SIC: 2834 Pharmaceutical Preparations